Progress in pediatric vasculitis

Current Opinion in Rheumatology

Volumn 21, Issue 5, 2009, Pages 538-546

  O'Neil, Kathleen M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Henoch Schonlein purpura; Kawasaki disease; Primary angiitis of the central nervous system; Vasculitis; Wegener granulomatosis

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY; ULINASTATIN; WARFARIN;

ANAPHYLACTOID PURPURA; ANEURYSM; AORTA ARCH SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM PRIMARY VASCULITIS; CHURG STRAUSS SYNDROME; DRUG DOSE REDUCTION; DRUG MEGADOSE; FAMILIAL MEDITERRANEAN FEVER; HUMAN; HYPERTENSION; HYPOTHERMIA; IMMUNOGLOBULIN A NEPHROPATHY; INFECTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MICROSCOPIC POLYANGIITIS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SINUS BRADYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; VASCULITIS; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; CHILD; CHURG-STRAUSS SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PURPURA, SCHOENLEIN-HENOCH; TAKAYASU ARTERITIS; VASCULITIS; VASCULITIS, CENTRAL NERVOUS SYSTEM; WEGENER GRANULOMATOSIS;

EID: 69649091076     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832f13f1     Document Type: Review

References (75)

1. Chung S, Seo P. Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol 2009; 21:3-9.
2. Saulsbury F. Clinical update: Henoch-Schonlein purpura. Lancet 2007; 369:976-978.
3. Prais D, Amir J, Nussinovitch M. Recurrent Henoch-Schonlein purpura in children. J Clin Rheumatol 2007; 13:25-28.
4. Gershoni-Baruch R, Broza Y, Brik R. Prevalence and significance of mutations in the familial Meditrranean fever gene in Henoch-Schonlein purpura. J Pediatr 2003; 143:658-661. (Pubitemid 37452797)
5. Tekin M, Yalcinkaya F, Tumer N, et al. Familial Mediterranean fever: renal involvement by diseases other than amyloid. Nephrol Dial Transplant 1999; 14:475-479. (Pubitemid 29062821)
6. Ozdogan H, Arisoy N, Kasapcapur O, et al. Vasculitis in familial Mediterranean fever. J Rheumatol 1997; 2:323-327.
7. Saatci U, Ozen S, Ozdemir S, et al. Familial Mediterranean fever in children: report of a large series and discussion of the risk and prognostic factors of amyloidosis. Eur J Pediatr 1997; 8:619-623. (Pubitemid 27351849)
8. Özkaya O, Bek K, Alaca N, et al. Cerebral vasculitis in a child with Henoch-Schonlein purpura and familial Mediterranean fever. Clin Rheumatol 2007; 26:1729-1732.
9. Balbir-Gurman A, Nahir A, Braun-Moscovici Y. Vasculitis in siblings with familial Mediterranean fever: a report of three cases and review of the literature. Clin Rheumatol 2007; 26:1183-1185. (Pubitemid 46863975)
10. Unal S, Gucer S, Kale G, et al. Severe Henoch-Schonlein purpura in a thalassemic patient under deferiprone treatment. Am J Hematol 2008; 83:165-166.
11. Wickiser J, Saulsbury F. Henoch-Schonlein purpura in a child with hyperimmunoglobulinemia D and periodic fever syndrome. Pediatr Dermatol 2005; 22:138-141. (Pubitemid 40471479)
12. Lau K, Wyatt R, Moldoveanu Z, et al. Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura. Pediatr Nephrol 2007; 22:2067-2072. (Pubitemid 350090713)
13. Peru H, Soylemezoglu O, Gonen S, et al. HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies. Clin Rheumatol 2008; 27:5-10. (Pubitemid 350182671)
14. Gok F, Ugur Y, Ozen S, Dagdeviren A. Pathogenesis-related adhesion molecules in Henoch-Schonlein vasculitis. Rheumatol Int 2008; 28:313-316. This study details expression of adhesion molecules in Hsp, perhaps by identifying new targets for treatment strategies.
15. Fessatou S, Nicolaidou P, Gourgiotis D, et al. Endothelin 1 levels in relation to clinical presentation and outcome of Henoch Schonlein purpura. BMC Pediatr 2008; 8:33. This recent study examines the role of ET-1 in Hsp.
16. Tahan F, Dursun I, Poyrazoglu H, et al. The role of chemokines in Henoch Schonlein purpura. Rheumatol Int 2007; 27:955-960. (Pubitemid 47084242)
17. Ece A, Kelekçi S, Kocamaz H, et al. Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch-Schönlein purpura. Clin Rheumatol 2008; 27:163-169.
18. Julian B, Wittke S, Haubitz M, et al. Urinary biomarkers of IgA nephropathy and other IgA-associated renal diseases. World J Urol 2007; 25:467-476.
19. Julian B, Wittke S, Novak J, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007; 28:4469-4483. (Pubitemid 350259049)
20. Shenoy M, Bradbury M, Lewis M, Webb N. Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression. Pediatr Nephrol 2007; 22:1717-1722. (Pubitemid 47337426)
21. Butani L, Morgenstern B. Long-term outcome in children after Henoch-Schönlein purpura nephritis. Clin Pediatr 2007; 46:505-511. (Pubitemid 46920338)
22. Lee J, Clayton F, Shihab F, Goldfarb-Rumyantzev A. Successful treatment of recurrent Henoch-Schonlein purpura in a renal allograft with plasmapheresis. Am J Transplant 2008; 8:228-231.
23. Oki E, Tsugawa K, Suzuki KS, et al. Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy. Rheumatol Int 2008; 28:1181-1182.
24. Weiss P, Feinstein J, Luan X, et al. Effects of corticosteroid on Henoch-Schonlein purpura: a systematic review. Pediatrics 2007; 120:1079-1087. (Pubitemid 350085543)
25. Pinna G, Kafetzis D, Tselkas O, Skevaki C. Kawasaki disease: an overview. Curr Opin Infect Dis 2008; 21:263-270. This is a comprehensive overview of current knowledge in Kawasaki disease.
26. Lin Y-J, Wan L, Wu J-Y, et al. HLA-E gene polymorphism associated with susceptibility to Kawasaki disease and formation of coronary artery aneurysms. Arthritis Rheum 2009; 60:604-610.
27. Oh J, Han J, Lee S, et al. Polymorphisms of human leukocyte antigen genes in Korean children with Kawasaki disease. Pediatr Cardiol 2008; 29:402-408.
28. Hong Y, Jin H-S, Park I, Hong S-J. Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children. Heart Vessels 2008; 23:341-347.
29. Huang F-Y, Chang T-Y, Chen M-R, et al. Genetic polymorphisms in the CD40 ligand gene and Kawasaki disease. J Clin Immunol 2008; 28:405-410.
30. Ikeda K, Ihara K, Yamaguchi K, et al. Genetic analysis of MMP gene polymorphisms in patients with Kawasaki disease. Pediatr Res 2008; 63:182-185. This is an intriguing study investigating variations in proteolytic enzymes, MMPs, in vessel destruction in Kawasaki disease.
31. Onouchi Y, Onoue S, Tamari M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004; 12:1062-1068. (Pubitemid 39600134)
32. + T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003; 111:E140-E147.
33. Brogan P, Shah V, Clarke L, et al. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol 2007; 151:267-274.
34. Suganami Y, Kawashima H, Hasegawa D, et al. Clinical application of rapid assay of serum interleukin-6 in Kawasaki disease. Pediatr Int 2008; 50:264-266. This study demonstrates that IL-6 is a predicator of risk of resistance to IVIG therapy.
35. Wittkowski H, Hirono K, Ichida F, et al. Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 2007; 56:4174-4181. (Pubitemid 350262345)
36. Cheung Y-F,OK, Woo C, et al. Oxidative stress in children late after Kawasaki disease: relationship with carotid atherosclerosis and stiffness. BMC Pediatr 2008; 8:20. (Pubitemid 351771248)
37. Kurio G, Zhiroff K, Jin L, et al. Noninvasive determination of endothelial cell function in the microcirculation in Kawasaki syndrome. Pediatr Cardiol 2008; 29:121-125. This report is an interesting study of endothelial function in children with Kawasaki disease that demonstrates abnormal microvascular endothelial function and improvement after resolution of the acute disease.
38. Borzutzky A, Gutiérrez M, Talesnik E, et al. High sensitivity C-reactive protein and endothelial function in Chilean patients with history of Kawasaki disease. Clin Rheumatol 2008; 27:845-850. This intriguing study demonstrates that years after Kawasaki disease, the DBP and CRP are abnormal years after acute Kawasaki disease resolution.
39. Popper S, Shimizu C, Shike H, et al. Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol 2007; 8:R261. (Pubitemid 351917513)
40. Abe J, Ebata R, Jibiki T, et al. Elevated granulocyte colony-stimulating factor levels predict treatment failure in patients with Kawasaki disease. J Allergy Clin Immunol 2008; 122:1008-1013. Gene expression arrays in Kawasaki disease implicated G-CSF in active disease and in poor outcome in Kawasaki disease.
41. Rowley A, Eckerley C, Jack H, et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997; 159:5946-5955. (Pubitemid 127471530)
42. Rowley A, Baker S, Shulman S, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005; 192:1757-1766. (Pubitemid 41587826)
43. Rowley A, Baker S, Shulman S, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One 2008; 3:e1582. (Pubitemid 351843803)
44. Rowley A, Baker S, Orenstein J, Shulman S. Searching for the cause of Kawasaki disease: cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol 2008; 6:394-401. This study summarized work that identified RNA-containing intracytoplasmic inclusions in cells of children dying from Kawasaki disease, suggesting a viral pathogenesis to Kawasaki disease. (Pubitemid 351552660)
45. Tremoulet A, Best B, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117-121.
46. Moreno N, Mendez-Echevarra A, de Inocencio J, et al. Coronary involvement in infants with Kawasaki disease treated with intravenous c-globulin. Pediatr Cardiol 2008; 29:31-35.
47. Uehara R, Belay E, Maddox R, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27:155-160.
48. Cha S, Yoon M, Ahn Y, et al. Risk factors for failure of initial intravenous immunoglobulin treatment in Kawasaki disease. J Korean Med Sci 2008; 23:718-722.
49. Satoru Iwashima S, Seguchi M, Matubayash T, Ohzeki T. Ulinastatin therapy in Kawasaki disease. Clin Drug Invest 2007; 27:691-696.
50. Newburger J, Sleeper L, McCrindle B, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663-675. (Pubitemid 46257229)
51. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009; 168:181-185. This study examines IVMP as an initial treatment in children with Kawasaki disease.
52. Furukawa T, Kishiro M, Akimoto K, et al. Effects of steroid pulse therapy on immunoglobulin resistant Kawasaki disease. Arch Dis Child 2008; 93:142-146. (Pubitemid 351204755)
53. Miura M, Kohno K, Ohki H, et al. Effects of methylprednisolone pulse on cytokine levels in Kawasaki disease patients unresponsive to intravenous immunoglobulin. Eur J Pediatr 2008; 167:1119-1123.
54. Lee T, Kim K, Chun J-K, Kim D. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008; 49:714-718.
55. Elbers J, Benseler S. Central nervous system vasculitis in children. Curr Opin Rheumatol 2008; 20:47-54. This is a summary of investigations and clinical experience of the largest group that collected experience in children with CNS vasculitis in childhood. (Pubitemid 351339431)
56. Benseler S, Silverman E, Aviv R, et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006; 54:1291-1297. (Pubitemid 43672942)
57. Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis with prominent leptomeningeal enhancement: a subset with a benign outcome. Arthritis Rheum 2008; 58:595-603. (Pubitemid 351294897)
58. Akikusa J, Schneider R, Harvey E, et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Care Res 2007; 57:837-844. (Pubitemid 46932091)
59. Levi M, Kodsi S, Rubin S, et al. Ocular involvement as the initial manifestation of Wegener's granulomatosis in children. J AAPOS 2008; 12:94-96.
60. Levine D, Akikusa J, Manson D, et al. Chest CT findings in pediatric Wegener's granulomatosis. Pediatr Radiol 2007; 37:57-62. (Pubitemid 44843050)
61. Villa-Forte A, Clark T, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine 2007; 86:269-277. (Pubitemid 47415005)
62. Patel A, Lehman T. Rituximab for severe refractory pediatric Wegener granulomatosis. J Clin Rheumatol 2008; 14:278-280. This is a provocative case report of a single patient treated with Wegener granulomatosis resistant to many treatments.
63. Wilkinson N, Page J, Uribe A, et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J Rheumatol 2007; 34:224-226. (Pubitemid 46106587)
64. Cabral D, O'Neil K, Higgins G, et al. Pediatric Wegener's granulomaotosis (WG): preliminary data from a US/Canadian registry of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. In: 2008 ACR Kestone Pediatric Rheumatology Symposium. Keystone, Colorado: American College of Rheumatology; 2008.
65. Ozen S, Ruperto N, Dillon M, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936-941.
66. Uribe A, Cabral D, Espinosa V. Logistic difficulties in implementing an unfunded multicentric pilot registry for pediatric chronic vasculitis: an initiative of the Childhood Arthritis and Rheumatology Research Alliance (CARRA). In: 2008 Keystone Pediatric Rheumatology Symposium. Keystone, Colorado: American College of Rheumatology; 2008.
67. Sinico R, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss Syndrome. Arthritis Rheum 2005; 52:2926-2935. (Pubitemid 41369124)
68. Nathani N, Little M, Kunst H, et al. Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax 2008; 63:883-888.
69. Harrold L, Patterson M, Andrade S, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). Pharmacoepidemiol Drug Saf 2007; 16:620-626. (Pubitemid 47039528)
70. Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum 2007; 56:3159-3166. (Pubitemid 47502764)
71. Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibodynegative Churg-Strauss syndrome, but not with Wegener's granulomatosis. Arthritis Rheum 2008; 58:1839-1848. (Pubitemid 351847539)
72. Tann O, Tulloh R, Hamilton M. Takayasu's disease: a review. Cardiol Young 2008; 18:250-259.
73. Chauhan S, Singh M, Nityanand S. Reactivity of g/d T Cells to human 60-kd heat-shock protein and their cytotoxicity to aortic endothelial cells in Takayasu arteritis. Arthritis Rheum 2007; 56:2798-2802. (Pubitemid 47237300)
74. Molloy E, Langford C, Clark T, et al. Antitumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67:1567-1569.
75. Filocamo G, Buoncompagni A, Viola S, et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J Pediatr 2008; 153: 432-434. This small case series of TNF inhibition in Takayasu arteritis in children suggests possible efficacy in some patients with Takayasu arteritis.